

Amtagvi™ (Lifileucel) Prior Authorization Form

Member Name: _____ Date of Birth: _____ Member ID#: _____

Drug Information

Physician billing (HCPCS code: _____) Pharmacy billing (NDC: _____)

Dose: _____ Regimen: _____ Start Date (or date of next dose): _____

Billing Provider Information

Provider NPI: _____ Provider Name: _____

Provider Phone: _____ Provider Fax: _____

Prescriber Information

Prescriber NPI: _____ Prescriber Name: _____

Prescriber Phone: _____ Prescriber Fax: _____ Specialty: _____

Criteria

For Authorization: (Approvals will be for 1 dose per member per lifetime):

1. Please include the most recent office visit note or clinical summary from the hospital to support your request. Is this information attached? Yes ___ No ___

2. Please indicate the diagnosis and information:

Melanoma

A. Is diagnosis unresectable or metastatic melanoma? Yes ___ No ___

B. Was member previously treated with a PD-1 inhibitor? Yes ___ No ___

C. Is disease BRAF V600 mutation positive? Yes ___ No ___

i. If yes, was member previously treated with a BRAF inhibitor with or without a MEK inhibitor? Yes ___ No ___

D. Will lifileucel be administered in an inpatient hospital setting with an intensive care facility and specialists skilled in cardiopulmonary or intensive care medicine available?

Yes ___ No ___

Other: _____

Additional Information: _____

Prescriber Signature: _____ **Date:** _____

I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge. Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy
Pharmacy Management Consultants
Product Based Prior Authorization Unit

Fax: 1-800-224-4014
Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.